Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(02): 139-143
DOI: 10.1055/s-0042-1742616
Case Report with Review of Literature

Megestrol Acetate in the Treatment of Post COVID-19 Fatigue in a Patient of Advanced Cancer: A Case Report and Mini Review of Literature

Chaitanya R Patil
1   Department of Pain and Palliative care, Kolhapur Cancer Center, Kolhapur, Maharashtra, India
,
Nilesh A Dhamne
2   Department of Medical Oncology, Kolhapur Cancer Center, Kolhapur, Maharashtra, India
,
Prasad K Tanawade
3   Department of Radiation Oncology, Kolhapur Cancer Center, Kolhapur, Maharashtra, India
,
Namrata B Mestri
4   Department of Pathology, DY Patil Medical College, Kolhapur, Maharashtra, India
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Megestrol acetate is one of the pharmacological agents used for cancer-associated fatigue. To date, there are no studies on its use in the treatment of post-COVID-19 (coronavirus disease 2019) fatigue. So, we report a case of metastatic carcinoma lung with a partial response with three cycles of palliative chemotherapy. He was contracted with mild COVID-19 infection post three cycles of his chemotherapy. Post this episode, fatigue was his main and most troublesome symptom. After a thorough clinical history, physical examination, and investigations, type 2 post-COVID-19 syndrome was diagnosed. After explaining the risks and benefits, we started the patient on low-dose megestrol acetate (160 mg/d per oral) with low to moderate benefits. However, upon increasing the dose to 480 mg/d, the benefit on the subjective quality of life was significant. Studies with a larger sample and randomized controlled trials have to be conducted to substantiate the hypothesis and actual effect of megestrol acetate in the treatment of post-COVID-19 fatigue.

Keywords

post COVID-19 syndrome - advanced cancer - fatigue - megestrol acetate

Source of Support

None.




Publication History

Article published online:
14 April 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Rosenthal TC, Majeroni BA, Pretorius R, Malik K. Fatigue: an overview. Am Fam Physician 2008; 78 (10) 1173-1179
    PubMedGoogle Scholar
  • 2 Greenberg DB. Clinical dimensions of fatigue. Prim Care Companion J Clin Psychiatry 2002; 4 (03) 90-93
    CrossrefPubMedGoogle Scholar
  • 3 Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000; 37 (4, suppl 6): 14-17
    CrossrefPubMedGoogle Scholar
  • 4 Flechtner H, Bottomley A. Fatigue and quality of life: lessons from the real world. Oncologist 2003; 8 (1, suppl 1): 5-9
    CrossrefPubMedGoogle Scholar
  • 5 Yoo EH, Choi ES, Cho SH, Do JH, Lee SJ, Kim JH. Comparison of fatigue severity and quality of life between unexplained fatigue patients and explained fatigue patients. Korean J Fam Med 2018; 39 (03) 180-184
    CrossrefPubMedGoogle Scholar
  • 6 Garrigues E, Janvier P, Kherabi Y. et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect 2020; 81 (06) e4-e6
    CrossrefPubMedGoogle Scholar
  • 7 Scordo KA, Richmond MM, Munro N. Post-COVID-19 syndrome: theoretical basis, identification, and management. AACN Adv Crit Care 2021; 32 (02) 188-194
    CrossrefPubMedGoogle Scholar
  • 8 Maltezou HC, Pavli A, Tsakris A. Post-COVID syndrome: an insight on its pathogenesis. Vaccines (Basel) 2021; 9 (05) 497
    CrossrefPubMedGoogle Scholar
  • 9 Mantovani G, Macciò A, Madeddu C. et al. Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. Oncologist 2010; 15 (02) 200-211
    CrossrefPubMedGoogle Scholar
  • 10 Bruera E, Ernst S, Hagen N. et al. Effectiveness of megestrol acetate in patients with advanced cancer: a randomized, double-blind, crossover study. Cancer Prev Control 1998; 2 (02) 74-78
    PubMedGoogle Scholar
  • 11 Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 1991; 7 (02) 6-9
    CrossrefPubMedGoogle Scholar
  • 12 Aguilar RB, Hardigan P, Mayi B. et al. Current understanding of COVID-19 clinical course and investigational treatments. Front Med (Lausanne) 2020; 7: 555301
    CrossrefPubMedGoogle Scholar
  • 13 Thevarajan I, Buising KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust 2020; 213 (03) 134-139
    CrossrefPubMedGoogle Scholar
  • 14 Schwartz LH, Litière S, de Vries E. et al. RECIST 1.1-Update and clarification: from the RECIST committee. Eur J Cancer 2016; 62: 132-137
    CrossrefPubMedGoogle Scholar
  • 15 Becker RC. COVID-19 and its sequelae: a platform for optimal patient care, discovery and training. J Thromb Thrombolysis 2021; 51 (03) 587-594
    CrossrefPubMedGoogle Scholar
  • 16 Morens DM, Breman JG, Calisher CH. et al. The origin of COVID-19 and why it matters. Am J Trop Med Hyg 2020; 103 (03) 955-959
    CrossrefPubMedGoogle Scholar
  • 17 Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res 2020; 24: 91-98
    CrossrefPubMedGoogle Scholar
  • 18 Bhandari S, Bhargava A, Sharma S, Keshwani P, Sharma R, Banerjee S. Clinical profile of COVID-19 infected patients admitted in a tertiary care hospital in North India. J Assoc Physicians India 2020; 68 (05) 13-17
    PubMedGoogle Scholar
  • 19 de Souza R, Mhatre S, Qayyumi B. et al. Clinical course and outcome of patients with COVID-19 in Mumbai city: an observational study. BMJ Open 2021; 11 (05) e042943
    CrossrefPubMedGoogle Scholar
  • 20 Budhiraja S, Soni A, Jha V. et al. Clinical profile of first 1000 COVID-19 cases admitted at tertiary care hospitals and the correlates of their mortality: an Indian experience. medRxiv 2020:2020.11.16.20232223
    Google Scholar
  • 21 Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ 2020; 370: m3026
    CrossrefPubMedGoogle Scholar
  • 22 Maccarone MC, Magro G, Tognolo L, Masiero S. Post COVID-19 persistent fatigue: a proposal for rehabilitative interventions in the spa setting. Int J Biometeorol 2021; 65 (12) 2241-2243
    CrossrefPubMedGoogle Scholar
  • 23 Vink M, Vink-Niese A. Could cognitive behavioural therapy be an effective treatment for long COVID and post COVID-19 fatigue syndrome? Lessons from the Qure Study for Q-Fever Fatigue Syndrome. Healthcare (Basel) 2020; 8 (04) E552
    CrossrefPubMedGoogle Scholar
  • 24 Balog DL, Epstein ME, Amodio-Groton MI. HIV wasting syndrome: treatment update. Ann Pharmacother 1998; 32 (04) 446-458
    CrossrefPubMedGoogle Scholar
  • 25 Loprinzi CL, Ellison NM, Goldberg RM, Michalak JC, Burch PA. Alleviation of cancer anorexia and cachexia: studies of the Mayo Clinic and the North Central Cancer Treatment Group. Semin Oncol 1990; 17 (6, suppl 9): 8-12
    PubMedGoogle Scholar
  • 26 Gill PG, Gebski V, Snyder R. et al. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol 1993; 4 (09) 741-744
    CrossrefPubMedGoogle Scholar
  • 27 Yeh S-S, Schuster MW. Megestrol acetate in cachexia and anorexia. Int J Nanomedicine 2006; 1 (04) 411-416
    CrossrefPubMedGoogle Scholar
  • 28 Ruiz-García V, López-Briz E, Carbonell-Sanchis R, Bort-Martí S, Gonzálvez-Perales JL. Megestrol acetate for cachexia-anorexia syndrome. A systematic review. J Cachexia Sarcopenia Muscle 2018; 9 (03) 444-452
    CrossrefPubMedGoogle Scholar
  • 29 Currow DC, Glare P, Louw S. et al. A randomised, double blind, placebo-controlled trial of megestrol acetate or dexamethasone in treating symptomatic anorexia in people with advanced cancer. Sci Rep 2021; 11 (01) 2421
    CrossrefPubMedGoogle Scholar
  • 30 Loprinzi CL, Michalak JC, Quella SK. et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331 (06) 347-352
    CrossrefPubMedGoogle Scholar
  • 31 Yeh S, Wu SY, Levine DM. et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000; 4 (04) 246-251
    PubMedGoogle Scholar
  • 32 Argilés JM, Anguera A, Stemmler B. A new look at an old drug for the treatment of cancer cachexia: megestrol acetate. Clin Nutr 2013; 32 (03) 319-324
    CrossrefPubMedGoogle Scholar
  • 33 House L, Seminerio MJ, Mirkov S. et al. Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica 2018; 48 (10) 973-983
    CrossrefPubMedGoogle Scholar
  • 34 Saeed S, Tadic M, Larsen TH, Grassi G, Mancia G. Coronavirus disease 2019 and cardiovascular complications: focused clinical review. J Hypertens 2021; 39 (07) 1282-1292
    CrossrefPubMedGoogle Scholar
  • 35 Mitrani RD, Dabas N, Goldberger JJ. COVID-19 cardiac injury: Implications for long-term surveillance and outcomes in survivors. Heart Rhythm 2020; 17 (11) 1984-1990
    CrossrefPubMedGoogle Scholar
  • 36 Webmd.com. Interactions of Megestrol acetate [updated 20 Feb 2020]. Accessed November 23, 2021 at: https://www.webmd.com/drugs/2/drug-8946-8300/megestrol-oral/megestrol-suspension-oral/details/list-interaction-medication
    Google Scholar
  • 37 Go.drugbank.com. Drug interactions with Megestrol acetate [updated 20 Feb 2020]. Accessed November 23, 2021 at: https://go.drugbank.com/drugs/DB00351
    Google Scholar